Niacin/simvastatin
Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the vitamin niacin and the statin drug simvastatin. It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008.[1] On April 15, 2016, the FDA pulled the approval of niacin and fibrates used in combination with statin drugs, citing growing evidence that the benefits of combining niacin or fibrate drugs with statin drugs to not outweigh the risks, compared to statin therapy alone.[2] This ruling applied to Advicor in addition to Simcor.[2]
 | |
 | |
| Combination of | |
|---|---|
| Niacin | Vitamin |
| Simvastatin | Statin |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| (verify) | |
References
- "Drugs.com, Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management". Retrieved 2008-03-15.
- "AbbVie Inc.; Withdrawal of Approval of New Drug Applications for ADVICOR and SIMCOR". U.S. Federal Register. 18 April 2016. Retrieved 17 May 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.